Oral Immunonutrition Therapy to Reduce Acute Toxicity After Neoadjuvant Chemoradiotherapy Pancreatic Cancer Patients
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorSun Yat-sen University
About this trial
A prospective, single-arm clinical trial is conducted to investigate the role of oral immunonutrion in reducing acute toxicity after neoadjuvant chemoradiotherapy among pancreatic cancer patients.
Eligibility criteria
Qualifiers
1. Pathologically confirmed pancreatic ductal epithelial malignant tumors;
2. Resectable pancreatic cancer treated with neoadjuvant chemoradiotherapy, or nonresectable locally advanced pancreatic cancer treated with neoadjuvant or radical chemoradiotherapy;
3.Nutritional Risk Screening 2002 (NRS2002) ≥3 and Patient-Generated Subjective Global Assessment (PG-SGA) performance status B;
4. Age 18 years and older;
Disqualifiers
1. Known allergy or intolerance to any component of investigational Oral Immunonutrition;
2. History of Oral Immunonutrition use within one month prior to enrollment;
3. Tumor compresses the major duodenal papilla, and /or appeared jaundice, acute pancreatitis;
4. Patients with contraindications for antineoplastic therapy, such as coronary heart disease, cerebral infarction, cerebral hemorrhage or other serious diseases;
Trial design
Treatments tested in this trial
- Oral Immunonutrition
Treatment groups
98 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov